Butantan Foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2010
NCT01218685
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

live, attenuated, dengue serotype 1, 2, 3, 4 virus (1 trial)

tetravax-dv-tv003 (1 trial)

Drugs in Other Trials (1)

inactivated influenza vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dengue (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3